About: REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.14 (-8.11%)
RGNX NASDAQ Regenxbio Inc
Regenxbio Inc share price
RGNX price activity
Last Price
$7.140
Change (24hr)
-0.63 USD (-8.11%)
Volume
741.56K
Volume (4w avg)
-
Open
$7.66
Day Range
$7.14 - $7.66
Previous Close
$7.77
Last Trade
13 Oct, 6:03 pm GMT+0
Delayed
13 Oct, 6:03 pm GMT+0
RGNX price performance
Delayed
13 Oct, 6:03 pm GMT+0
RGNX Market Signals